A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study

BACKGROUND: A recent phase III trial did not confirm the previous clinical and endoscopic improvements seen in patients with Crohn’s disease (CD) receiving Mongersen, an oral Smad7 antisense oligonucleotide. Factors accounting for such a discrepancy are unknown. OBJECTIVE: Our objective was to furth...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BioDrugs
Glavni autori: Marafini, Irene, Stolfi, Carmine, Troncone, Edoardo, Lolli, Elisabetta, Onali, Sara, Paoluzi, Omero Alessandro, Fantini, Massimo C., Biancone, Livia, Calabrese, Emma, Di Grazia, Antonio, Monteleone, Ivan, Lenti, Marco Vincenzo, Di Sabatino, Antonio, Monteleone, Giovanni
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2021
Teme:
Original Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8084825/
https://ncbi.nlm.nih.gov/pubmed/33871807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-021-00482-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items